Provided by Tiger Trade Technology Pte. Ltd.

Akari Therapeutics PLC

0.3454
-0.0567-14.10%
Post-market: 0.34550.0001+0.03%17:13 EST
Volume:16.27M
Turnover:7.25M
Market Cap:12.34M
PE:-0.61
High:0.5999
Open:0.4512
Low:0.3166
Close:0.4021
52wk High:1.73
52wk Low:0.3166
Shares:35.74M
Float Shares:5.62M
Volume Ratio:124.61
T/O Rate:289.41%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.5691
EPS(LYR):-1.6570
ROE:-197.24%
ROA:-34.20%
PB:0.54
PE(LYR):-0.21

Loading ...

Company Profile

Company Name:
Akari Therapeutics PLC
Exchange:
NASDAQ
Establishment Date:
- -
Employees:
9
Office Location:
22 Boston Wharf Road,Floor 7,Boston,Massachusetts,United States
Zip Code:
02210
Fax:
929 274 7553
Introduction:
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities. The company also develops PASylated-nomacopan, which is in preclinical development for the treatment of geographic atrophy secondary to dry age-related macular degeneration; and hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA) combined with nomacopan, which is in phase 3 clinical development for the treatment of pediatric HSCT-TMA. The company is headquartered in Boston, Massachusetts.

Directors

Name
Position
Abizer Gaslightwala
Director,President and Chief Executive Officer
Hoyoung Huh
Chairman
James Neal
Director
Robert Bazemore
Director
Samir R. Patel
Director
Sandip I. Patel
Director

Shareholders

Name
Position
Abizer Gaslightwala
Director,President and Chief Executive Officer
Kameel Farag
Interim Chief Financial Officer